Geode Capital Management LLC Has $364.67 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Geode Capital Management LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 0.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,733,660 shares of the life sciences company’s stock after purchasing an additional 5,833 shares during the quarter. Geode Capital Management LLC owned about 1.72% of Illumina worth $364,670,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Versant Capital Management Inc boosted its holdings in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new position in Illumina in the 4th quarter worth $32,000. Assetmark Inc. increased its holdings in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina in the 4th quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina in the fourth quarter valued at about $48,000. 89.42% of the stock is owned by institutional investors.

Illumina Trading Down 3.0 %

Shares of NASDAQ:ILMN opened at $74.16 on Friday. Illumina, Inc. has a 12-month low of $70.64 and a 12-month high of $156.66. The business has a 50 day moving average of $96.82 and a 200-day moving average of $125.10. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a market cap of $11.75 billion, a PE ratio of -9.66, a P/E/G ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ILMN shares. Barclays restated an “underweight” rating on shares of Illumina in a research note on Tuesday, March 11th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and reduced their target price for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Canaccord Genuity Group lowered their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, March 11th. Morgan Stanley reduced their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Finally, Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.